Provided by Tiger Trade Technology Pte. Ltd.

Harmony Biosciences Holdings, Inc.

37.05
-0.2200-0.59%
Volume:70.34K
Turnover:2.59M
Market Cap:2.13B
PE:11.70
High:37.36
Open:37.27
Low:36.44
Close:37.27
52wk High:40.87
52wk Low:25.52
Shares:57.60M
Float Shares:44.56M
Volume Ratio:0.43
T/O Rate:0.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.17
EPS(LYR):2.51
ROE:25.93%
ROA:13.20%
PB:2.56
PE(LYR):14.76

Loading ...

Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares

Reuters
·
Jan 29

Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares

Reuters
·
Jan 21

Harmony Biosciences : Needham Raises Target Price to $46 From $42

THOMSON REUTERS
·
Jan 20

Harmony Biosciences Holdings (HRMY) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Jan 13

BRIEF-Harmony Biosciences Guides To Over $1 Billion In Wakix® Revenue In 2026 Advancing Robust Late-Stage Pipeline With Potential For Long-Term Value Creation

Reuters
·
Jan 12

Harmony Biosciences Q4 Prelim Unaudited Net Product Revenue $243 Mln

THOMSON REUTERS
·
Jan 12

Harmony Biosciences: Wakix Net Revenue Projected Between $1.0 Bln - $1.04 Bln for 2026

THOMSON REUTERS
·
Jan 12

Harmony Biosciences Projects WAKIX Revenue to Surpass $1 Billion in 2026

Reuters
·
Jan 12

Harmony Biosciences Is Maintained at Buy by Truist Securities

Dow Jones
·
Jan 09

Harmony Biosciences price target lowered to $45 from $48 at Truist

TIPRANKS
·
Jan 08

Harmony Biosciences to Present at J.P. Morgan Healthcare Conference

Reuters
·
Jan 07

Jeffrey M. Dayno, President and CEO, Reports Disposal of Harmony Biosciences Holdings Inc. Common Shares

Reuters
·
Dec 18, 2025

BRIEF-Beacon Biosignals Announces Partnership With Harmony Biosciences

Reuters
·
Dec 16, 2025

Harmony Biosciences Partners with Beacon Biosignals to Advance EEG-Based Sleep Disorder Trials

Reuters
·
Dec 16, 2025

Beacon Biosignals Announces Partnership With Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative Eeg

THOMSON REUTERS
·
Dec 16, 2025

Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares

Reuters
·
Dec 10, 2025

Harmony Biosciences Reports Promising Phase 3 Data for EPX-100 in Dravet Syndrome

Reuters
·
Dec 08, 2025

Harmony Biosciences (HRMY) Is Up 7.6% After GR Pitolisant Bioequivalence Win and Patent Runway Push

Simply Wall St.
·
Dec 05, 2025

Harmony Biosciences Unveils New Phase 3 ARGUS Trial Data on EPX-100 for Dravet Syndrome

Reuters
·
Dec 02, 2025

Mizuho Raises Price Target on Harmony Biosciences Holdings to $46 From $39, Keeps Outperform Rating

MT Newswires Live
·
Dec 01, 2025